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Summary
Background: Proton pump inhibitors (PPIs) are well tolerated in the short term but 
have recently been associated with increased long- term cardiovascular risk in obser-
vational studies.
Aims: To evaluate long- term risks of myocardial infarction (MI) and ischaemic stroke 
(IS) associated with PPI vs H2- receptor antagonist (H2RA) therapy in adults without 
pre- existing cardiovascular or cerebrovascular disease
Methods: Using administrative claims data (2008– 2018), we emulated a target trial 
comparing MI and IS risks in new users of PPIs vs H2RAs. Treatment was identified 
using dispensed prescriptions. MI and IS were defined using hospital discharge codes. 
Inverse probability weighting was used to adjust for confounding, and Cox models to 
estimate hazard ratios (HRs). Survival curves were estimated using weighted Kaplan- 
Meier estimators.
Results: We identified 1 143 948 new users of PPIs and 36 229 new users of H2RAs 
who were free of prevalent cardiovascular or cerebrovascular disease. The mean fol-
low- up time was 6.2 years for PPI initiators and 5.3 years for H2RA initiators. After 
10 years, the HRs for MI and IS were 0.96 (95% confidence interval (CI): 0.80- 1.16) 
and 0.98 (95% CI: 0.89- 1.08), respectively.
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1  | INTRODUC TION
Proton pump inhibitors (PPIs) are widely used to treat disorders 
characterized by excessive gastric acid production.1 For more than 
a decade, PPIs have also been sold over- the- counter and are often 
consumed without medical supervision. The long- term risk of PPI in-
take has received considerable attention in recent years, with large 
and well- controlled cohort studies linking PPI use to an increased 
risk of myocardial infarction (MI), ischaemic stroke (IS)2- 6 and car-
diovascular death.7 The elevated risk was associated with PPI use 
but not with the use of H2- receptor antagonists (H2RAs), the most 
commonly used alternative class of medications to treat acid- related 
gastrointestinal conditions.8 A potential mechanism to explain an in-
creased long- term cardiovascular risk is that intake of PPIs inhibits 
the enzyme dimethylarginine dimethylaminohydrolase and might 
thereby impair endothelial nitric oxide production and vascular en-
dothelial function. This pathway has been established ex vivo, in 
mice9 and was recently observed in humans.10
In contrast, a large randomized controlled trial with 3 years of 
follow- up found no increased risk for MI or IS in patients with stable 
cardiovascular disease and peripheral artery disease.11 Similarly, a 
large analysis of administrative claims data found no increased risk 
for a first MI during PPI intake of up to 3 years,12 and an analysis of 
68 514 women enrolled in the Nurses’ Health Study found no in-
creased risk for primary IS in prevalent users of PPIs.13
However, if PPI intake was to cause vascular damage and there-
fore increase the risk for cardiovascular disease, an observational 
window of more than 3 years might be necessary, especially for pa-
tients without pre- existing cardiovascular conditions. We conceptu-
alized an emulation of a target trial14 to examine the long- term effect 
of PPI vs H2RA therapy on the risk of MI and IS in a general popula-
tion without prior cardiovascular events.
2  | METHODS
2.1 | Data source
For this study, we analysed claims data from the Allgemeine 
Ortskrankenkasse (AOK) Bayern, a large regional German Statutory 
Health Insurance Provider. The dataset included about 6.1 million 
adult persons, who received health insurance cover from the AOK 
Bayern for at least 2 years since January 2007. Outpatient and hos-
pital diagnoses were coded according to the German Modification 
of the International Statistical Classification of Diseases and Related 
Health Problems (ICD- 10- GM), released by the German Institute 
of Medical Documentation and Information (DIMDI).15 Drugs 
purchased over- the- counter, or administered in hospital, are not 
contained in the database. For data protection reasons, the data 
were pseudonymized. The study received approval from the Ethics 
Committee of the LMU Munich and the institutional review board 
of the AOK Bayern. It was registered at ENCePP.eu (EUPAS31559), 
where the study protocol, including a detailed description of the 
emulated target trial, was deposited. The investigators had full con-
trol over protocol development, analyses and publication. Patients 
or the public were not involved in the design, or conduct, or report-
ing, or dissemination plans of our research. This study adhered to the 
RECORD- PE guidelines.16
2.2 | Study population
The study cohort included new users of PPIs and new users of H2RAs, 
who started therapy between 2009 and 2018. We demanded no prior 
treatment with PPIs or H2RAs with at least 1year of medical history 
before treatment initiation recorded in the data. Cohort entry was the 
day of the first dispensed prescription of any of those drugs. All pa-
tients were required to be at least 18 years old and free of prevalent 
cardiovascular (ICD- Codes I21, I22, I23, I24.1, I25.2) or cerebrovas-
cular disease (ICD- Codes I60, I61, I63, I64, G46) at cohort entry. A 
graphical depiction of our study design is shown in Figure 1.17
2.3 | Medication exposure, follow- up and outcomes
New users of PPIs (ATC Code A02BC) were compared to new users of 
H2RAs (ATC Code A02BA), as the use of an active comparator might 
reduce the potential for confounding by indication, compared to a non- 
user control.18 We defined exposure by identifying drug dispensing 
in prescription claims. Follow- up for study outcomes started the day 
after initiation of treatment and continued in an ‘as- started’ approach19 
until the occurrence of an outcome of interest, death, disenrollment 
or the end of the study period on 31 December 2018 (Figure 1).17 The 
two study endpoints were primary MI and primary IS. Patients were 
considered a case of MI or IS after a hospital admission with the cor-
responding main discharge diagnosis (MI: I21; IS: I63, G46.5, G46.6). 
The validity of these claims- based diagnoses has been established.20,21
2.4 | Covariates
We controlled for several confounders, assuming that direct causes 
of the exposure or outcome, excluding possible instrumental vari-
ables, would identify a sufficient set of confounding variables.22 
Accordingly, we adjusted for demographics (age, sex and nationality), 
Conclusions: This analysis of claims data of a large German health insurer did not pro-
vide evidence that PPI therapy increased the risk of MI or IS in the first decade after 
treatment initiation.
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calendar time of inclusion (in quarters and years), relevant comor-
bidities and medications. It remains unclear, whether treatment indi-
cation (e.g. gastroesophageal reflux disease [GERD]) has any direct 
or indirect effect on our outcomes.23 Therefore, adjusting for treat-
ment indication could mean adjusting for an instrumental variable, 
and introduce bias instead of reducing it. Despite that, we included 
treatment indications in the model for the propensity scores to mini-
mize unmeasured confounding and indication bias.24 Patient base-
line characteristics were measured during the 90 days before and 
including the date of cohort entry. We also adjusted for the number 
of concurrently used drugs and the Elixhauser comorbidity score,25 
adapted to administrative data, taking both inpatient and outpatient 
diagnoses into account.26 Due to intrinsic properties of the data, 
both were measured in the quarter preceding treatment initiation. 
A complete list of baseline patient characteristics and a definition of 
covariates are provided in Tables S1 and S2.
2.5 | Statistical analysis
We used inverse probability of treatment (IPT) weighting to ad-
just for confounding.27 Propensity scores were estimated from a 
confounder- adjusted logistic regression model and used to calculate 
stabilized weights.28 Standardized mean differences were used to 
assess balance in patient characteristics between treatment groups 
before and after weighting.29 Raw incidence rates per 1000 person- 
years were computed. Overall exposure- specific survival was plot-
ted as adjusted Kaplan- Meier estimates.30,31 We estimated hazard 
ratios (HRs) with the corresponding 95% confidence intervals (CI) 
using weighted Cox proportional hazards models with robust stand-
ard errors. Sensitivity analyses included a comparison of PPI initia-
tors with non- initiators, and the consideration of 97 pre- selected 
negative control (tracer) outcomes (NCOs)32 to detect potential un-
measured confounding. We imposed various lag times by excluding 
F I G U R E  1   Study design [Colour figure can be viewed at wileyonlinelibrary.com]
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events that occurred during the first 10, 30, 90 and 180 days after 
baseline.33 The statistical software R (version 3.6.3, Foundation for 
Statistical Computing) was used.
3  | RESULTS
We identified 1 143 948 initiators of PPI therapy and 36 229 initia-
tors of H2RA therapy meeting the eligibility criteria in our data set 
of 6 097 740 individuals. 22 020 PPI initiators and 16 201 H2RA 
initiators received both medications during follow- up. Rates per 
1000 person- years of MI and IS by exposure group are presented 
in Table 1. Covariate summaries of PPI and H2RA initiators, before 
and after weighting, are provided in Table 2 and Table S1. In the un-
weighted data, patients who started PPI therapy were older, more 
likely to suffer from GERD or Helicobacter pylori infection, and 
more likely to take non- steroidal anti- inflammatory drugs or antico-
agulants. After weighting, both groups were well balanced on the 
confounders.
We found no evidence for an association of PPI vs H2RA initia-
tion with MI or IS. The HR comparing PPI and H2RA initiation over 
10 years was 0.96 (95% CI: 0.80- 1.16) for MI and 0.98 (95% CI: 0.89- 
1.08) for IS. HRs for several follow- up periods are given in Table 3. 
Survival curves comparing the outcome- free survival among initi-
ators of PPI therapy vs H2RA therapy were consistent with these 
findings (Figures 2 and 3). The HRs for comparing PPI initiators and 
non- initiators were 1.02 (95% CI: 0.94- 1.10) for MI and 0.98 (95% 
CI: 0.94- 1.02) for IS (Table 3). The lag time approach did not sub-
stantially change point estimates or precision (Table 3). The negative 
control analysis pointed to a small potential of unmeasured con-
founding influencing our observed HRs (Figure S1).
4  | DISCUSSION
We estimated the long- term effect of PPI compared to H2RA ther-
apy on MI and IS risk in adults without pre- existing cardiovascular 
disease. Our analyses do not indicate an increased risk of MI or IS 
in the first decade after PPI therapy. PPIs are among the most fre-
quently used medications.1 This makes their safety an important 
clinical concern.
Our study adds information to the safety evaluation of PPIs. Large 
and well- controlled cohort studies had linked PPI use to an increased 
risk of MI and IS,2– 6 but more recently these concerns have been atten-
uated. In a large study using administrative claims data from commer-
cial and Medicare Supplemental plans, researchers found no increase 
in risk of primary MI during PPI intake of up to 3 years.12 In addition, 
a large randomized trial with 17 598 participants comparing pantopra-
zole intake vs placebo over 3 years showed no increase in the overall 
cardiovascular risk.11 This study included patients with stable cardio-
vascular disease and peripheral artery disease, while our study included 
subjects without the history of cardiovascular conditions. Also, an anal-
ysis of 68 514 women enrolled in the Nurses’ Health Study found no 
increased risk for primary IS in prevalent users of PPIs.13
Given that some patients use PPIs for many years,34 an observational 
window of more than 3 years might be necessary, especially for patients 
without prevalent cardiovascular disease at baseline, if PPI intake was to 
cause vascular damage and thereby increase cardiovascular risk.
The study has several limitations. First, exposure was identified 
using dispensed prescriptions. Use of over- the- counter (OTC) med-
ications and combination products (ATC Code A02BD) was not in-
cluded in our exposure definition. This means that prevalent OTC 
users might have been included in our cohort, regardless of the 1- 
year exclusion period before study entry. We assumed that therapy 
is usually initiated by a physician, and therefore new users were well 
captured by our approach.
Another limitation is that our estimates relied on the assumption 
that the measured baseline covariates were sufficient to adjust for 
confounding. Large- scale randomized trials provide the most reliable 
evidence to detect small to moderate effects, while observational 
studies always remain under the risk of unadjusted confounding.
Only a minority of PPI and H2RA initiators had any condition 
that would indicate therapy at the start of treatment. This made 
control for confounding by indication more difficult. At the same 
time, it made it suitable to create a second control group of non- 
initiators that did not start any treatment at all. Indication bias 
might have played different roles at different times of our study. 
During the initial phase of our observation period PPIs were re-
garded as the more modern and effective drug, but later on 
concerns about the safety of PPIs were raised following a FDA 
warning regarding a clopidogrel- omeprazole interaction in 2009.35 
We addressed these issues by analysing 97 pre- selected negative 
Myocardial infarction Ischaemic stroke
H2RA PPI H2RA PPI
Number of individuals 36 229 1 143 948 36 229 1 143 948
Person- years 226 051 6 091 226 224 733 6 054 149
Average days under risk 2277 1944 2264 1932
Number of events 156 4450 595 17 798
Crude rate per 1000 
person- years
0.69 0.73 2.65 2.94
Abbreviations: H2RA, histamine- 2 receptor antagonist; PPI, proton pump inhibitor.
TA B L E  1   Characteristics regarding 
the ‘as- started’ analysis in the raw/
unweighted datasets of new users
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control (tracer) outcomes and found it unlikely that unmeasured or 
residual confounding would bias the estimates away from the null.
We performed an ‘as- started’19 analysis capturing the long- term 
effect of PPI therapy understood as a point treatment and thereby 
neglecting any effects of dose or duration of PPI intake. This ap-
proach is ideal to address the long- term effect of PPI therapy, if 
intake causes irreversible vascular damage, but has limited power 
to detect effects, if only high- dose or long- term intake were to raise 
the cardiovascular risk.
Finally, many H2RA initiators switched to PPIs later on and 
H2RA initiators were much more likely to switch to a PPI than vice 
versa. Switching medication does bias the estimate towards the 
TA B L E  2   Baseline characteristics for initiators of PPI or H2RA before/after inverse probability of treatment weighting
Unweighted population Weighted population
H2RA PPI SMD H2RA PPI SMD
N 36 229 1 143 948 36 282 1 143 952
Age (years)a  49.3 (16.6) 51.1 (16.5) 0.113 51.4 (16.5) 51.1 (16.5) 0.017
Female (%) 60.1 55.9 0.085 56.4 56.0 0.007
German (%) 80.1 80.8 0.018 80.6 80.8 0.006
Quarter of inclusionb  0.402 0.106
Baseline- Yearb  0.393 0.084
Elixhauser Scorea  1.22 (4.36) 1.19 (4.34) 0.007 1.26 (4.46) 1.19 (4.34) 0.015
Number of Comedicationsa  1.48 (2.09) 1.44 (2.02) 0.015 1.47 (2.06) 1.45 (2.02) 0.014
Medications (%)
Antidiabetic drugs 4.6 5.2 0.026 5.3 5.2 0.005
Antiplatelets 1.1 0.9 0.018 0.9 0.9 0.001
Anticoagulants 3.0 5.7 0.134 6.0 5.6 0.016
Non- steroidal anti- 
inflammatory drugs
29.3 34.6 0.114 33.5 34.4 0.019
Statins 3.9 4.2 0.013 4.2 4.1 0.002
Aspirin 0.8 0.7 0.010 0.8 0.7 0.004
Clopidogrel 0.4 0.2 0.040 0.2 0.2 0.003
Selective serotonin 
reuptake inhibitors
2.2 2.5 0.021 2.6 2.5 0.005
Comorbidities (%)
Obesity 8.5 9.1 0.022 9.2 9.1 0.003
Diabetes 8.7 10.1 0.048 10.4 10.0 0.013
Chronic pulmonary disease 12.3 12.5 0.006 12.8 12.5 0.007
Hypertension 23.2 26.4 0.075 26.8 26.3 0.010
Renal failure 2.0 2.7 0.047 2.9 2.7 0.012
Liver disease 6.7 8.3 0.059 8.6 8.2 0.014
Indications (%)
Gastro- oesophageal reflux 
disease
8.4 14.7 0.200 15.4 14.5 0.024
Oesophagitis 0.2 0.4 0.036 0.5 0.4 0.007
Gastritis 18.0 21.5 0.089 21.9 21.4 0.012
Duodenal ulcer 0.4 1.2 0.080 1.2 1.1 0.009
Peptic ulcer 0.1 0.1 0.004 0.1 0.1 0.001
Zollinger- Ellison syndrome 0.0 0.0 0.008 0.0 0.0 0.002
Helicobacter pylori 0.3 1.5 0.123 1.6 1.5 0.012
Heartburn 2.9 2.5 0.027 2.5 2.5 0.002
aContinuous variables with (mean (standard deviation)). PPI, proton pump inhibitor; H2RA, H2- receptor antagonist; SMD, standardized mean 
difference
bFor details on the balance of the factor variables ‘Quarter of inclusion’ and ‘Baseline- Year’ see Table S1.
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null. However, this problem did not affect the comparison with non- 
initiators, which resulted in similar estimates.
Despite these limitations, this study represents a significant con-
tribution to the literature on the safety of PPIs. The large cohort size, 
the very good capture of acute cardiovascular outcomes in hospital 
records, the use of an active comparator in combination with high- 
dimensional IPT- weighting for confounding control and an extensive 
analysis of negative control outcomes make this study a highly reliable 
source of information with a moderate risk of bias.36
In summary, for patients with no history of MI or IS PPI therapy 
does not appear to increase the risk of MI or IS in the first decade 
after treatment initiation; any presumed effect is moderate, at most. 
Thus, physicians and patients should not avoid starting an indicated 
PPI therapy because of concerns related to increased cardiovascular 
TA B L E  3   Hazard ratios of weighted Cox regression models (As- started analysis)
Comparator Follow- up time
Myocardial infarction Ischaemic stroke
HR CI P HR CI P
PPI vs H2RA Full Study (FS) [10 years] 0.96 0.80- 1.16 0.68 0.98 0.89- 1.08 0.65
1 year 1.17 0.70- 1.96 0.55 1.12 0.86- 1.46 0.41
2 years 1.11 0.77- 1.62 0.57 1.14 0.94- 1.38 0.17
3 years 1.01 0.76- 1.35 0.94 1.05 0.89- 1.25 0.54
4 years 0.97 0.76- 1.25 0.82 1.04 0.90- 1.21 0.57
6 years 0.90 0.74- 1.10 0.31 0.98 0.87- 1.10 0.73
8 years 0.94 0.78- 1.13 0.51 0.98 0.88- 1.08 0.67
PPI vs No intake FS 1.02 0.94- 1.10 0.70 0.98 0.94- 1.02 0.32
PPI vs H2RA FS, Lag Time (LT): 10 days 0.95 0.79- 1.15 0.61 0.97 0.88- 1.08 0.61
FS, LT: 30 days 0.96 0.80- 1.16 0.69 0.97 0.88- 1.07 0.58
FS, LT: 90 days 0.95 0.78- 1.15 0.59 0.98 0.88- 1.08 0.65
FS, LT: 180 days 0.99 0.81.1.20 0.90 0.98 0.88- 1.08 0.65
Abbreviations: CI, 95% confidence interval; H2RA, H2- receptor antagonist; HR, hazard ratio; PPI, proton pump inhibitor; P, P- value.
F I G U R E  2   As- started: PPI vs H2RA— baseline adjusted survival (Kaplan- Meier) curve for myocardial infarction [Colour figure can be 
viewed at wileyonlinelibrary.com]






















Number at risk: n (%)
365 730 1095 1460 1825
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1143952 (100) 1043402 (91) 951855 (83) 843483 (74) 735341 (64) 627326 (55) 515415 (45) 397711 (35) 276975 (24) 145879 (13) 551 (0)
H2RA
PPI
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risk. Further studies should examine the effects of long- term and 
high- dose intake of PPIs.
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